TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Use of IMSI in Poor Responders to IVF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* poor ovarian response~Exclusion Criteria:~* body mass index (BMI) ≥ 30 kg/m2~* presence of endocrinopathies (e.g., diabetes, hyperprolactinemia, hypothyroidism)~* altered karyotype or documented genetic defects in one or both partners~* history of chronic, autoimmune or metabolic diseases~* altered meiosis in testicular biopsy or altered sperm-FISH~* teratozoospermia~* participation, simultaneously or within the previous 6 months, in another clinical trial with medication

- Gender: FEMALE
- Minimum Age: 37 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI)
- Control (Type: ACTIVE_COMPARATOR): Intracytoplasmic sperm injection (ICSI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TAP Block Using Liposomal Bupivacaine for Post-cesarean Delivery Analgesia- Walking Towards Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients between the ages of 18 and 45 presenting for cesarean delivery~2. ASA-1, ASA-2, ASA-3~3. No allergy to morphine~4. No allergy to bupivacaine~5. Patients with BMI \> 45 will be excluded~6. No history of anxiety~7. No recent or chronic opioid use~Exclusion Criteria:~1. Need for Magnesium sulfate therapy~2. Neonatal admission to neonatal intensive care unit~3. Need for additional surgery other than cesarean delivery +/- bilateral tubal ligation (e.g. hysterectomy, cystotomy)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Control group (Bupivacaine) (Type: ACTIVE_COMPARATOR): Patient will receive intrathecal morphine and TAP block with plain bupivacaine.
- Liposomal Bupivacaine (Type: EXPERIMENTAL): Patient will receive intrathecal morphine + TAP block with Liposomal bupivacaine and bupivacaine 0.25%
- Bupivacaine + dexamethasone and methylprednisolone (Type: ACTIVE_COMPARATOR): Patient will receive intrathecal morphine + TAP block with only bupivacaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Detection of Arousal With Facial Micro-expression in Severe Brain-damaged Patient

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Brain-damaged patient (stroke, traumatic brain injury, anoxia)~* Disorder of consciousness (CRS-R≤ 10) more than 48h after stopping sedation~* Patient without spontaneous or stimulated facial expressions~Exclusion Criteria:~* Medically unstable patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Severe brain-damaged patient in coma awakening (Type: EXPERIMENTAL): For each patient, video sessions of the face will be performed during a waking period, until the spontaneous macro-EFE (Emotional Facial Expression) reappears. The video sessions will be done without stimulation or with visual, auditory or tactile stimulation. The sessions will be daily for 7 days then weekly for a maximum duration of 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prediction of Delayed Toxic Cardiomyopathy in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
ANTHRA GROUP~Inclusion Criteria:~* Patients who were treated with anthracyclines for malignant disease between the ages of 0 and 18~* Patient aged 11 to 27 years~* Included in the SpeckleAnthra Study (NCT02893787)~* Discontinued chemotherapy for more than 6 years~* Patient in remission of malignant disease~* Enrolled in a social security plan~* Written informed consent from at least one legal representative for the minor patient/ Written informed consent for patients of legal age~Exclusion Criteria:~* Onset of active malignancy or recurrence of malignancy after the Speckle Anthra study that required resumption of chemotherapy or mediastinal radiotherapy.~* Chronic cardiac, pulmonary or muscular pathology of etiology other than secondary to anthracycline therapy~* For adult patients: subject under guardianship or curators~CONTROL GROUP~Inclusion Criteria:~* Control patient included in the Speckle Control study (NCT02056925)~* Had a cardiological consultation with echocardiography performed for a banal reason (heart murmur test, cardiological symptoms) and whose result was normal~* No chronic disease or long-term drug treatment~Exclusion Criteria:~* Refusal to participate in the study by the patient and/or parents or legal guardian after receipt of the study's information and non-objection note.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 27 Years
- Healthy Volunteers: t

Study Arms:
- Anthra2 (Type: EXPERIMENTAL): Patient will have an echocardiography with speckle tracking analysis 5 years after the end of their participation to SpeckleAnthra study (NCT02893787)
- Control (Type: ACTIVE_COMPARATOR): Cardiac ultrasound analysis with speckle tracking of age- and sex-matched healthy patients in the Anthra2 group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Taliderm® and Vacuum-assisted Closure (VAC) for Treatment of Pressure Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ischial/sacral Pressure ulcer between 4 and 15cm diameter~* Greater than or equal to 18 years of age~* Ability to obtain informed consent~Exclusion Criteria:~* Connective tissue disorders~* Immunosuppression, Hemodialysis, Steroids~* Pregnancy~* Sepsis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- wound dressing with VAC (Type: SHAM_COMPARATOR): After wound debridement wounds are treated for 2 weeks with VAC dressing alone
- wound dressing with VAC and sNAG under Antiaggregation (Type: OTHER): In patients being under antiaggregation with Aspirin® 100mg daily, after wound debridement wounds are treated with VAC and sNAG
- wound dressing with VAC and sNAG without antiaggregation (Type: EXPERIMENTAL): In patients NOT being under antiaggregation, after wound debridement wounds are treated with VAC and sNAG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted with acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction) and referred for coronary angiography.~* Current therapy with clopidogrel (at least 300mg loading dose, or 75mg po daily for \>5 days)~* Age range 21-75 years.~Exclusion Criteria:~* Unable to give consent~* Age younger than 21 years, greater than 75 years~* History of stroke~* Body weight \<60 kg~* Acute STEMI,~* Thrombocytopenia\<100'000,~* requirement for chronic warfarin therapy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TEG (Type: OTHER): Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA\<69
- Light transmittance aggregometry (Type: OTHER): Clopidogrel non-response defined as MPA ADP \>42.9% Clopidogrel response defined as MPA ADP \<42.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight ≥ 10 kg~* Age ≥ 4 years~* Diagnosis of Rett syndrome based on consensus clinical criteria and patients with MECP2 duplications will not be eligible.~* Has at least 10 episodes of breathing dysrhythmia, defined by episodes ≥10 seconds of breath holding (apnea), per hour during cardiorespiratory monitoring~* Ability to take study medication provided either as capsules or combined with food/drink.~* Patient is cooperative, willing to complete all aspects of the study, and capable of doing so with assistance of a caregiver.~Exclusion Criteria:~* Meets any of the diagnostic exclusion criteria for Rett syndrome, Typical (Neul et al, 2010);~* Patient is participating in a clinical trial with another investigational drug~* Hypersensitivity to sarizotan or other 5-HT1a agonists;~* Current clinically significant (as determined by Investigator) cardiovascular, respiratory (e.g. severe asthma), gastrointestinal, renal, hepatic, hematologic or other medical disorders, in addition to those directly related to the patient's Rett syndrome;~* QTcF interval on the ECG is greater than 450 msec.~* Surgery planned during the study (except for insertion of gastrostomy tube);~* Severe diabetes mellitus or fatty acid oxidation disorder.~* Ophthalmologic history including any of the following conditions: albino patients, family history of hereditary retinal disease, retinitis pigmentosa, any active retinopathy or severe diabetic retinopathy.~* Females who are pregnant, breastfeeding, or of childbearing potential and not using a hormonal contraceptive.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sarizotan low dose (Type: EXPERIMENTAL): 2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg 5 mg bid (≥13 years of age and weighing ≥25 kg)
- Sarizotan high dose (Type: EXPERIMENTAL): 5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg 10 mg bid (≥13 years of age and weighing ≥25 kg)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo bid for 24 wks DB age 4 and above

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Transplant for MDR Pathogen Decolonization

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Renal transplant patient inclusion criteria:~* 18 years or older~* Able to provide informed consent~* Positive for one of the target MDR organisms by rectal or stool culture tests~FMT stool donor inclusion criteria:~* Able to provide informed consent~* Able to complete donor screening~* Able to adhere to FMT stool collection and testing procedures~Renal transplant patient exclusion criteria:~* Still in hospital at week 7 following organ transplantation~* Pregnant or planning to become pregnant~* Breastfeeding~* Participating in another interventional or investigational study~* Neutropenic (ANC \< 0.5)~* Colonized with Clostridium difficile~* Presence of colostomy or ileostomy~* Has an active intestinal infection~* Fever \> 38.0 or WBC count \> 15,000~* Are taking a non-dietary probiotic supplement~* Require or are expected to require systemic antimicrobial therapy other than Pneumocystis prophylaxis or cytomegalovirus (CMV) therapy during the study period~* Has a severe underlying disease with anticipated survival less than 6 months~* Are unable to tolerate FMT or enema for any reason, or where their physician believes for any reason that FMT might pose a health risk to the subject~* Subjects who report a history of anaphylactoid food allergy will not be excluded but these allergies will be noted and donors will be required to avoid ingestion of these foods for at least three days prior to donation~FMT stool donor exclusion criteria:~* Presence of any of the following by stool examination: vancomycin-resistant Enterococci (VRE), Salmonella, Shigella, shiga toxin-producing E. coli, Yersinia, Campylobacter, ESBL or carbapenemase-producing Enterobacteriaceae (CRE), pathogenic ova or parasites, C. difficile toxin B (by PCR), or rotavirus, adenovirus and norovirus~* History of any type of active cancer aside from melanoma~* Risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C, prion or any neurological disease as determined by the donor questionnaire~* History of gastrointestinal comorbidities, e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation or diarrhea, or colostomy or ileostomy~* Receipt of blood transfusion from a country other than Canada in the preceding 6 months~* Antibiotic use or any systemic immunosuppressive agents in the 3 months prior to stool donation~* Receipt of any live vaccine within 3 months prior to stool donation~* Any current or previous medical or psychosocial condition or behaviors which in the opinion of the investigator may pose risk to the recipients or the donor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Female Acl Prevention Study Where we Look at Landing Techniques Pre/Post Nine Week Strenghtening Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:females only age 13-16 -~Exclusion Criteria:all males females younger than 13 and older than 16~-

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Problems and Changes in Body Composition in Patients With Non-small Cell Lung Cancer (LEKS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of NSCLC.~* No other active cancer.~* Must be able to consent.~* Fluent in Norwegian.~Exclusion Criteria:~* Other active cancer than NSCLC~* Younger than 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: None): All with diagnose of NSCLC in Oslo during 6 months
- Cohort 2 (Type: None): All NSCLC in Ulleval university hospital whom are in need of palliative chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CPAP Reduces Hypoxemia After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing cardiac surgery on cardiopulmonary bypass~* PaO2 /FiO2 \< 200 after extubation~* extubation time \< 24 h.~Exclusion Criteria:~* patients \< 18 years old~* extracorporeal membrane oxygenation~* severe cardiac dysfunction (FE\<25%)~* mechanical ventilation before the intervention~* severe COPD (patients on oxygen therapy, with a FEV1\< 50%)~* heart or lung transplantation~* lack of consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TREATMENT (Type: EXPERIMENTAL): Helmet CPAP
- CONTROL (Type: ACTIVE_COMPARATOR): Venturi Mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Impact of Video Discharge Instructions for Mohs Surgery Post-Operative Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who underwent a linear closure on the face at UH Mohs clinic~* Fluent English speakers~Exclusion Criteria:~● Non-fluent English speakers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Video Discharge Instructions (Type: EXPERIMENTAL): These videos contain the same instructions that a patient receives via the standard-of-care verbal and written discharge instructions. These instructions will be delivered by the same nursing and medical staff that also regularly provides verbal and written discharge instructions to patients. There will be no difference in the content between the standard-of-care verbal and written instructions and the video discharge instructions. Patients in this group will receive telecommunication reminders on how to access discharge videos.
- Verbal and Written Discharge Instructions (Type: ACTIVE_COMPARATOR): Nursing and medical staff will provide verbal and written discharge instructions as is standard of care post surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced solid tumors for which standard treatment does not exist or is no longer effective.~* For chemotherapy combination treatment, must be suitable for treatment with either gemcitabine or pemetrexed.~* Relatively good overall health other than cancer.~Exclusion Criteria:~* Poor bone marrow function (not producing enough blood cells).~* Poor liver or kidney function.~* Serious heart conditions~* History of uncontrolled epilepsy, Parkinson's disease, Alzheimer's disease, brain tumor or any uncontrolled psychiatric or nervous system condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine (Type: EXPERIMENTAL): gemcitabine administered in combination with AZD6918
- pemetrexed (Type: EXPERIMENTAL): pemetrexed administered in combination with AZD6918
- AZD6918 (Type: EXPERIMENTAL): AZD6918 administered alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Acceptability Study of ACUAWARE

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients:~* Age 18 or older;~* experiencing chronic pain,~* complaint of 3+ months,~* score of 5 or greater on a 1-10 scale;~* able to provide informed consent~* willing to sign an approved consent form that conforms to federal and institutional guidelines,~* English speaking and writing.~Exclusion Criteria:~Prior or current diagnosis of:~* cancer,~* Multiple Sclerosis (MS),~* any Dementia,~* Parkinson's Disease,~* Autism Spectrum Disorder,~* Pregnancy,~* Fibromyalgia,~* Eating Disorder,~* Down's Syndrome~* Schizophrenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Persons with chronic pain (Type: None): Standard acupuncture care will be provided to persons (n=50) with chronic pain. Standard care is defined as the care a participant was already receiving and that care will not be interrupted in any way for any study participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children with ferritin levels \> 1000 ng/mL~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Children with high serum ferritin (Type: None): Children with very high serum ferritin levels and confirmed iron toxicity will have a urine sample and blood sample drawn at the same time. Both samples will have ferritin levels and iron content measured and compared for correlation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility